New imaging test for blood cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new imaging agent called 64Cu-LLP2A to see if it can better detect certain blood cancers like multiple myeloma and low-grade lymphomas. It aims to find tumors more clearly than standard scans, which could help your doctor plan the best care for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have multiple myeloma or a low-grade lymphoma (like follicular lymphoma, marginal zone lymphoma, or CLL).
- You need to lie still on your back for about 75 minutes inside a PET/CT scanner.
- You cannot have claustrophobia or conditions that would make the scan hard to complete.
- If you could become pregnant, you must have a negative pregnancy test before the scan.
- You can join even if you're taking part in other research studies with experimental drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging method called CXCR4 PET/CT that may help doctors better see and understand lymphomas (a type of blood cancer). It is for people who are newly diagnosed or suspected of having lymphoma and have already had a standard PET/CT.
This early-stage trial tests a new radioactive tracer called [68Ga]Ga-R54 that helps doctors see certain advanced cancers (like breast, lung, colon, ovary, pancreas, or multiple myeloma) on PET scans. The tracer targets a specific protein (CXCR4) found on cancer cells, which may help doctors better detect and understand your cancer.
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
This Phase 1 study tests a new special scan marker (a radioactive imaging agent) to see whether it can detect certain multiple myeloma spots in the body. If it works, it may help doctors better locate disease using a PET-style scan.
This study uses a special PET/MR scan with a tracer called 68Ga-Pentixafor to see if it can better find lymphoma and multiple myeloma spots in the body. It may help doctors get clearer pictures than standard scans.
This study tests a new type of PET scan called 68Ga-Pentixafor to see how well it finds and stages blood cancers (like non-Hodgkin lymphoma and myeloma). It will compare this new scan to the standard FDG-PET scan. If you join, you may get more accurate information about your cancer.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.